阅读理解　　Text 3 　　In 2010. a federal judge shook America's biotech industry to its core. Companies had won patents for isolated DNA for decades-by 2005 some 20% of human genes were parented. But in March 2010 a judge ruled that genes were unpatentable. Executives were violently agitated. The Biotechnology Industry Organisation (BIO)， a trade group， assured members that this was just a “preliminary step” in a longer battle. 　　On July 29th they were relieved， at least temporarily. A federal appeals court overturned the prior decision， ruling that Myriad Genetics could indeed holb patents to two genss that help forecast a woman's risk of breast cancer. The chief executive of Myriad， a company in Utah，said the ruling was a blessing to firms and patients alike. 　　But as companies continue their attempts at personalised medicine， the courts will remain rather busy. The Myriad case itself is probably not over Critics make three main arguments against gene patents： a gene is a product of nature， so it may not be patented； gene patents suppress innovation rather than reward it； and patents' monopolies restrict access to genetic tests such as Myriad's. A growing number seem to agree.Last year a federal task-force urged reform for patents related to genetic tests. In October the Department of Justice filed a brief in the Myriad case， arguing that an isolated DNA molecule “is no less a product of nature... than are cotton fibres that have been separated from cotton seeds. ” 　　Despite the appeals court's decision， big questions remain unanswered. For example， it is unclear whether the sequencing of a whole genome violates the patents of indivi dual genes within it. The case may yet reach the Supreme Court. 　　AS the industry advances ,however,other suits may have an even greater impact.companies are unlikely to file many more patents for human DNA molecules-most are already patented or in the public domain .firms are now studying how genes intcract,looking for correlations that might be used to determine the causes of disease or predict a drug’s efficacy,companies are eager to win patents for ‘connecting the dits’,expaains hans sauer,alawyer for the BIO. 　　Their success may be determined by a suit related to this issue, brought by the Mayo Clinic, which the Supreme Court will hear in its next term. The BIO rtcently held a convention which included seddions to coach lawyers on the shifting landscape for patents. Each meeting was packed.

单选题 it canbe learned from paragraph I that the biotech companies would like_________

【正确答案】 C

【答案解析】细节题。题目主干是“biotech companies would like...”，第一段提到“Companies had won patents for isolated DNA for decades-by 2005 some 20% of human genes were parented．But in March 2010 a judge ruled that genes were unpatentable．”几十年来，公司持有已分离DNA的专利权，约20%的人类基因已获得专利，但是2010年3月，法官判决基因不可获取专利权，令公司总裁大怒。得出公司想要获得是基因专利权。

单选题 those who are against gene patents believe that_________

【正确答案】 B

【答案解析】细节题。反对者的理由出现在第二段“Critics make three main arguments against gene patents：a gene is a product of nature，so it may not be patented；gene patents suppress innovation rather than reward it；and patents' monopolies restrict access to genetic tests．”原因有3个，分别是基因是自然之产物，基因专利权有碍创新，专利垄断限制人们使用基因测试。A项没有提到，而D项的逻辑主语被偷换了，C项说的与原文相反。故选B项。可能学生看到“only”一字，就不假思索排除它，选其他的选项。注意在考试时，应仔细核对原文。